Kamada Ltd Stock Price, News & Analysis

Kamada (NASDAQ: KMDA) will release its third quarter and nine months ended September 30, 2025 financial results on Monday, November 10, 2025 before U.S. market open. Management will host an investor conference call on November 10, 2025 at 8:30 AM Eastern Time to discuss results and answer questions.

Shareholders can join by phone using conference ID 13756537 (U.S.: 1-877-407-0792; Israel: 1-809-406-247; International: 1-201-689-8263) or listen via live webcast at https://viavid.webcasts.com/starthere.jsp?ei=1738840&tp_key=92257bc662.

Kamada (NASDAQ: KMDA) announced that Amir London, Chief Executive Officer, will present at the Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025 at 9:20 a.m. ET at the Lotte New York Palace Hotel in New York.

Mr. London will also be available for one-on-one investor meetings throughout the conference; investors should arrange meetings through their Stifel representative. A live webcast of the presentation will be available via the company-provided link.

Kamada (NASDAQ: KMDA), a global biopharmaceutical company specializing in rare conditions and specialty plasma-derived products, announced its participation in two major investor conferences in September 2025.

CEO Amir London will present at the Wells Fargo Healthcare Conference on September 3, 2025, at 3:45 PM ET, and the H.C. Wainwright Global Investment Conference on September 8, 2025, at 11:00 AM ET. One-on-one investor meetings will be available at both conferences, with live webcasts accessible through provided links.

Kamada (NASDAQ: KMDA) reported strong financial results for Q2 and H1 2025, with significant growth in both revenue and profitability. First half 2025 revenues reached $88.8 million, up 11% year-over-year, while Q2 revenues were $44.8 million, a 5% increase. The company's adjusted EBITDA for H1 2025 grew 35% to $22.5 million, representing a 25% margin.

Based on robust performance, Kamada raised its 2025 adjusted EBITDA guidance to $40-44 million and maintained revenue guidance of $178-182 million. The company received FDA approval for its Houston plasma collection center, with an estimated annual revenue potential of $8-10 million at full capacity. Additionally, Kamada continues to advance its Phase 3 InnovAATe clinical trial for inhaled Alpha-1 Antitrypsin therapy.

Kamada Ltd. (NASDAQ: KMDA) has received FDA approval for its plasma collection center in Houston, Texas, allowing commercial sales of normal source plasma. The 12,000 square foot facility features 50 donor beds with an annual collection capacity of 50,000 liters of plasma.

The Houston center, positioned to be one of the largest specialty plasma collection sites in the U.S., is expected to generate $8-10 million in annual revenue at full capacity. The facility will collect both normal source plasma and specialty plasma, including Anti-Rabies and Anti-D. This marks Kamada's third Texas-based site, alongside locations in San Antonio and Beaumont.

Kamada (NASDAQ: KMDA), a commercial stage biopharmaceutical company specializing in rare and serious conditions through plasma-derived products, has scheduled its Q2 and H1 2025 financial results announcement for August 13, 2025, before U.S. markets open.

The company will host an investment community conference call at 8:30 AM ET on the same day, where management will discuss results and take questions. Investors can join via phone or webcast, with specific dial-in numbers provided for U.S., Israeli, and international participants.

Kamada Ltd. (NASDAQ: KMDA) has confirmed the continuation of its operations and manufacturing activities at its Israeli facility despite ongoing events in the Middle East. The global biopharmaceutical company, which specializes in rare and serious conditions through plasma-derived products, assures that product availability worldwide will not be disrupted. While temporary shipping delays may occur due to closed Israeli airspace, the company's international distribution centers, partners, and distributors maintain adequate inventory levels to meet customer demands. CEO Amir London emphasizes their commitment to business continuity and employee well-being while closely monitoring the situation.

Kamada Ltd. (NASDAQ: KMDA) reported strong Q1 2025 financial results with revenues of $44.0 million, up 17% year-over-year, and adjusted EBITDA of $11.6 million, increasing 54%. Net income reached $4.0 million ($0.07 per share), up from $2.4 million in Q1 2024. The company maintains its 2025 guidance of $178-182 million in revenues and $38-42 million in adjusted EBITDA. Key developments include:

• Opening a new plasma collection center in San Antonio, TX, expected to generate $8-10 million in annual revenues
• Launch of CYTOGAM® post-marketing research program
• Secured a $25 million contract for KAMRAB and VARIZIG supply in Latin America (2025-2027)
• Continued progress in Phase 3 InnovAATe clinical trial for inhaled AAT therapy

The company maintains a strong cash position of $76.3 million and focuses on four strategic growth pillars: organic growth, M&A, plasma operations, and AAT program advancement.

Kamada Ltd. (NASDAQ: KMDA), a commercial stage biopharmaceutical company specializing in rare and serious conditions and plasma-derived products, has scheduled its Q1 2025 financial results announcement for May 14, 2025, before U.S. markets open.

The company will host a conference call for the investment community at 8:30am ET on the same day. Participants can join via phone using specific dial-in numbers for U.S., Israeli, and International callers, or watch the webcast live online.